Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Keros Therapeutics Inc
KROSCurrent price
56.62 USD
-3.73 USD (-6.18%)
Last closed
60.35 USD
Company
www.kerostx.com
ISIN
US4923271013
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
2 750 857 728 USD
Yield for 12 month
+86.99 %
1Y
3Y
5Y
10Y
15Y
KROS
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts. Address: 1050 Waltham Street, Lexington, MA, United States, 02421
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
91.67 USDP/E ratio
–Dividend Yield
–Current Year
+151 000 USD
Last Year
+20 000 000 USD
Current Quarter
+388 000 USD
Last Quarter
+37 000 USD
Current Year
-664 000 USD
Last Year
-1 615 000 USD
Current Quarter
+388 000 USD
Last Quarter
-269 000 USD
Key Figures KROS
1 year
3 years
5 years
10 years
EBITDA
-202 890 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-28.17 %
PEG Ratio
–
Return On Equity TTM
-43.82 %
Wall Street Target Price
91.67 USD
Revenue TTM
651 000 USD
Book Value
13.57 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
4750 %
Dividend Yield
–
Gross Profit TTM
-87 265 000 USD
Earnings per share
-5.22 USD
Diluted Eps TTM
-5.22 USD
Most Recent Quarter
III 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics KROS
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History KROS
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation KROS
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
3436.2975
Price Sales TTM
4225.588
Enterprise Value EBITDA
-13.0494
Price Book MRQ
5.1581
Financials KROS
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators KROS
For 52 weeks
27.31 USD
73 USD
50 Day MA
58.19 USD
Shares Short Prior Month
3 017 784
200 Day MA
55.27 USD
Short Ratio
7.71
Shares Short
2 721 108
Short Percent
10.17 %
BeatStart